[Webinar Archive Available] Orphan drug development in Japan - How can we accelerate rare disease patients’ access to therapies? -
Orphan drug development in Japan
- How can we accelerate rare disease patients’ access to therapies? -
The world rare disease market has grown and it should reach 24 Bio USD in 2024. Japanese rare disease market has a potential for growth, judging by the market growth of US and other dominant countries in EU, as nearly half of orphan drugs approved in Japan come from those countries. Many orphan drugs have not been approved in Japan yet and the medical needs remain largely unmet in this country.
Additionally, the regulatory process of orphan drugs in Japan is favorable to those drug approvals, however, it remains a challenge for many pharmaceutical companies to step into orphan drug development in Japan with lack of knowledge on Japan specific regulatory process and difficult access to trained staff.
President & Representative Director
OrphanPacific Inc., CMIC Group
President, NPO ASrid Japan